What Analgin bufus Treats: Main Uses and Benefits

Metamizole sodium (dipyrone), the active ingredient, is commonly applied in clinical settings that involve acute or unstable symptom patterns, offering short-term symptomatic assistance. Metamizole is commonly used to help with severe acute and chronic pain and fever in situations where supportive symptom management is appropriate. The application of metamizole is relevant for easing severe acute and chronic pain and fever.

Addressing Acute and Severe Pain States

Analgin bufus is commonly applied in scenarios where additional management of discomfort is required for moderate to severe pain, which may include post-traumatic injury, intense headaches, or musculoskeletal pain like myalgia and arthralgia. It is used across conditions marked by heightened symptom intensity where effective symptomatic support is crucial, contributing to easing the overall symptom load and supports the patient during difficult episodes.

Relief for Visceral Pain and Colic Spasms

A key use of the medication is relevant for easing visceral pain that is specifically accompanied by smooth muscle spasm, such as acute attacks of renal or biliary colic. This particular therapeutic benefit is relevant for easing the painful cramping and tension in internal organs, contributing to easing the overall symptom load during these highly distressing and episodic manifestations.

Management of High and Unresponsive Fever

The medication is also relevant in clinical settings for the control of severely elevated body temperature (fever). It is often applied during acute febrile phases, providing an antipyretic effect when symptoms become difficult to tolerate. This use helps address symptom clusters that may become intense, which contributes to overall comfort during symptomatic phases.

---

Quick Fact: Supportive Relief for Acute Symptoms
Primary Symptom Domains: Intense pain, visceral spasm, and high fever.
Symptom Severity Focus: Moderate to severe, acute, and episodic manifestations.
Patient Benefit: Supports general well-being by easing the overall symptom burden during difficult episodes.

Regulatory References

1. European Medicines Agency (EMA) review

The official regulatory profile for Analgin bufus (Metamizole Sodium) strictly defines the patient populations eligible for its use. The medicine is authorized for use in adults and adolescents 15 years of age or older, and in children from three months of age provided their body weight is 5 kg or more. Usage in children is determined by weight-based calculations.

Absolute Contraindications

Analgin bufus is formally contraindicated and must not be used in several defined populations. This includes individuals with any history of agranulocytosis caused by metamizole or related pyrazolone medicines. Use is also prohibited in patients with impaired bone marrow function, diseases of the blood-cell formation system, acute hepatic porphyria, or known hypersensitivity to the drug. The medicine is also contraindicated in infants below three months of age or those weighing less than 5 kg.

Conditional Use and Restrictions

Specific physiological states and conditions necessitate conditional use or restriction. The medicine is contraindicated during the third trimester of pregnancy. Use during the first six months of pregnancy is restricted and generally allowed only for a single dose when other options are unsuitable. Breastfeeding is not recommended, and if a single dose is administered, official guidance advises discarding breastmilk for a 48-hour period. Furthermore, official labeling mandates dose reduction or caution for older adults and patients with established renal or hepatic impairment.

This section outlines the officially documented interaction patterns of Metamizole Sodium (the active ingredient) as specified in government regulatory documents. The drug’s interaction profile is primarily defined by pharmacokinetic and pharmacodynamic constraints.

Pharmacokinetic Interactions and Exposure Reduction

The primary constraint is a pharmacokinetic interaction where the drug's metabolite acts as a moderate-to-strong inducer of hepatic enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction accelerates the clearance of co-administered medicines that are substrates for these enzymes, resulting in significantly reduced plasma concentrations and decreased systemic exposure.

• Exposure to the immunosuppressant Ciclosporin is formally reported to be substantially reduced, which can compromise its therapeutic level.
• Reduction in exposure has also been documented for sensitive substrates such as Midazolam, Efavirenz, and Omeprazole.

Pharmacodynamic and Procedural Restrictions

Interactions may also arise from combined physiological effects or chemical incompatibility:

• Co-administration with Methotrexate carries an official warning due to the additive risk for haematologic toxicity.
• Metamizole interferes with the anti-platelet effect of low-dose Acetylsalicylic acid (Aspirin). Official guidance suggests timing separation to mitigate this antagonism (e.g., taking aspirin at least 30 minutes prior to Metamizole).
• The injectable formulation carries a specific restriction: intravenous co-administration with Dihydralazine must be strictly avoided due to documented chemical incompatibility and decomposition of Dihydralazine.

Analgin bufus, containing metamizole, functions as a prodrug, undergoing rapid hydrolysis to its active metabolite, 4-methyl-amino-antipyrine (4-MAA), which subsequently metabolizes to 4-amino-antipyrine (4-AA). These metabolites permeate the blood-brain barrier to target central nervous system (CNS) pathways.

The primary mechanism involves the inhibition of cyclooxygenase-3 (COX-3), a splice variant of COX-1 predominantly expressed in the CNS. This inhibitory interaction reduces the enzymatic biosynthesis of prostaglandin E2 ( PGE2) within the brain and spinal cord. Decreased central PGE2 levels modulate neuronal firing and diminish the sensitivity of peripheral nociceptors, resulting in system-level physiological reduction of nociception and thermoregulatory setpoint.

Secondary mechanisms contributing to the overall pharmacodynamic profile include the interaction of 4-AA and related arachidonoyl amides as agonists toward the central cannabinoid type 1 ( CB1) receptors. This CB1 receptor activation contributes to disinhibition of descending antinociceptive pathways. Additionally, 4-MAA and 4-AA are linked to activation of the peripheral L-arginine/nitric oxide/cGMP pathway and inhibition of intracellular Ca^2+ release in smooth muscle cells, which modulates vascular tone and visceral contractility.

The administration of Metamizole Sodium solution for injection is based on standardized methods, frequency, and dose limits, reflecting its use in acute care settings. The injectable preparation is for parenteral administration only, specifically via deep intramuscular (IM) injection or by a slow intravenous (IV) route.

For adults and adolescents over 15 years, the usual single dose is up to 1,000 mg of Metamizole. This dose may be repeated, with a required minimum interval of six to eight hours between administrations, not exceeding a standard maximum total daily dose of 4,000 mg. The injectable form is designated for short-term use only to manage acute symptom patterns.

Specific instructions govern the administration procedure. When delivered intravenously, the injection must be administered very slowly to mitigate administration-related effects, and patient monitoring, including blood pressure and breathing, is required. The solution may be diluted with standard intravenous fluids such as 0.9% saline or 5% glucose solution and should be warmed to body temperature prior to use.

Dosing requires adjustment for specific patient groups. For children up to 14 years old, the dose is calculated based on body weight, using a range of 8 to 16 mg per kilogram. Furthermore, a dose reduction should be considered for older adult patients, as the elimination of the active metabolites may be slower.

Research evidence / Overview of studies for Analgin bufus (Metamizole Sodium)

---

Evidence for Acute and Post-Surgical Pain Management

This section will summarize the clinical research, primarily based on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses, that has examined the medicine's use for patients experiencing moderate to severe short-term pain, such as after injury or surgical procedures.

Studies monitored patient-reported outcomes describing perceived discomfort by measuring changes in pain intensity scores over defined time intervals. Studies reported measurements of pain reduction comparable to those observed with standard pain relievers that are not opioids in the immediate postoperative period. Research highlights patterns observed within the first hour of administration for the injectable form. Despite this, long-term outcomes are not fully established since the follow-up durations were limited in most acute-care studies.

Evidence for Visceral Pain and Spasms

This section will describe the studies, including comparative trials, that have specifically focused on the medicine's action in managing pain related to smooth muscle contractions, which includes acute attacks of renal or biliary colic.

Metamizole Sodium was studied for conditions characterized by episodic or acute changes. Research so far indicates that the medicine was observed in some studies to have a relevant pattern related to outcomes related to physical discomfort in these specific spasmodic conditions. However, comparative evidence is lacking in some areas, as sample sizes were modest in some of the colic-specific trials.

Evidence for High Fever that is Unresponsive to Other Treatments

This section will outline the comparative clinical trials and scientific reviews that have examined the medicine's profile for managing severely elevated body temperature when standard first-line fever-reducing agents are found to be insufficient or unsuitable.

Studies monitored the medicine's use in research contexts involving physiological strain or stress. Research describes the measured reduction in severely elevated body temperature. Studies reported a measurable change in fever in the observed populations. Certainty remains low for some specific patient subgroups, and comparative evidence is lacking for certain clinical settings where high fever may occur.

Key Research Gaps and Uncertainties

A significant limitation across the entire evidence landscape is that long-term outcomes are not fully established, particularly concerning use lasting longer than a few weeks. Furthermore, subgroup findings are uncertain for specific, complex patient groups who may be at higher risk due to pre-existing conditions. The evidence quality varies across studies, leading to some findings being mixed regarding its use in certain complex pain scenarios.

Common questions about Analgin bufus (FAQ)

---

Q: Is Analgin bufus the same as Metamizole?

The active ingredient in this medicine is Metamizole Sodium, which is also commonly referred to as Dipyrone. Analgin bufus is the specific brand name for the injectable solution (preparation) of this compound, which is intended for professional clinical use.

Q: Is Analgin bufus a non-steroidal anti-inflammatory drug (NSAID)?

Official classifications place this medicine in the distinct pyrazolones pharmacological class. While it has some properties that may reduce inflammation, it is not categorized as a conventional Non-Steroidal Anti-inflammatory Drug (NSAID) and does not share the same core mechanism of action.

Q: How quickly does Analgin bufus start working?

According to clinical data and official information, the effects for the injectable formulation are generally described as beginning within the first hour of administration.

Q: How long does the effect of Analgin bufus last?

Official regulatory documents define the required minimum interval between administrations as six to eight hours. The time interval between doses is officially defined as this duration.

Q: Can Analgin bufus be used for muscle pain or sprains?

The medicine's documented uses include managing acute severe pain, such as pain following injuries or surgical procedures. The spasmolytic property means it can address pain that involves smooth muscle contractions or cramps.

Q: Can Analgin bufus be used by people with asthma?

Official labeling states that use of this medicine is formally contraindicated, meaning it is prohibited, for individuals with a history of bronchial asthma that is known to be triggered by prostaglandins or other pain relievers.

Q: Are there any food restrictions when using Analgin bufus?

Official product information does not specify restrictions related to food consumption. However, co-consumption of alcohol is generally advised against due to the potential for cumulative effects with certain side effects of the medicine.

Q: Can Analgin bufus be used for tooth pain?

The general purpose of the medicine is to provide relief for acute severe pain. This may include short-term pain arising from issues such as dental problems or injuries requiring strong symptom control.

Q: Is it possible to use Analgin bufus for headache relief?

The documented uses include general relief for pain and fever. In specific circumstances, this may encompass the management of headaches requiring strong symptom control.

Q: Do you get tired or drowsy after using Analgin bufus?

Official regulatory documents list drowsiness and dizziness as possible, though uncommon, side effects of the medicine.

Q: Can Analgin bufus affect laboratory test results?

Yes, the active substance is described as potentially interfering with certain laboratory tests. This interference specifically involves the measurement of substances like serum creatinine, triglycerides, HDL cholesterol, and uric acid.

Q: Is Analgin bufus appropriate for people with kidney problems?

Official labeling states that caution is required for patients with pre-existing renal impairment (kidney problems). Official labeling mandates that a dose reduction is considered for these patients to account for slower elimination of the drug from the body.

Q: Is Analgin bufus habit-forming?

Metamizole is officially classified as a non-opioid analgesic and is not regulated as a controlled substance. This means it does not carry the same risk of dependence or addiction as opioid pain relievers.

Q: Are there different forms of Analgin bufus available (like tablets or liquid)?

Analgin bufus is specifically the injectable solution, which is used in clinical settings. However, the active ingredient Metamizole is available from various manufacturers in other oral formulations, including tablets and drops, in different regulatory jurisdictions.

Q: Is Analgin bufus available over-the-counter?

The injectable form (Analgin bufus) is designated for administration in a clinical setting by a healthcare professional. Consequently, it is not typically available for over-the-counter (OTC) use.

Q: What is the history of Analgin bufus use in medicine?

The active ingredient, Metamizole (Dipyrone), has a long history in medicine. Regulatory context reviews indicate it has been utilized in clinical practice since its introduction in the 1920s.

Q: Does Analgin bufus have a cooling effect on the body?

The medicine is classified as an antipyretic, meaning it works to reduce severely elevated body temperature. It achieves this by lowering the body’s core temperature set point, which is the physiological mechanism for fever reduction.

Q: What are the official restrictions on using Analgin bufus long-term?

Regulatory documents designate the medicine for short-term use only to manage acute symptoms. Long-term use is associated with known risks, such as the severe blood disorder agranulocytosis, which is the basis for the short-term designation.

Q: Does alcohol change the way Analgin bufus works?

Co-administration of alcohol may be associated with an additive risk for certain side effects, such as drowsiness or potential liver issues. Official safety advice indicates this combination may require avoidance.

Q: Can Analgin bufus be used for menstrual cramps?

The medicine possesses documented spasmolytic properties (relieves smooth muscle contraction). Its spasmolytic action means it can address pain that involves smooth muscle contractions, which may include discomfort related to menstrual cramps.

Q: Can Analgin bufus cause dizziness or affect driving?

Yes, the medicine may cause side effects like dizziness or affect a person's level of alertness. Official warnings state that it may impair concentration and the ability to drive or operate complex machinery.

Q: Is Analgin bufus available in combination with other medicines?

While Analgin bufus is a single-ingredient solution, the active ingredient Metamizole is available in some regulatory jurisdictions in combination with other active substances for specific therapeutic uses.

Q: Have there been recent studies on the safety profile of Analgin bufus?

Due to continuous safety monitoring, regulatory bodies, such as the European Medicines Agency (EMA), have initiated recent reviews (e.g., in 2024) to reassess the risk of known adverse reactions like agranulocytosis.

Q: Why do official sources list rare side effects for Analgin bufus?

Rare side effects, such as agranulocytosis and anaphylactic shock, are listed in official documents because they are documented events. Even though they are rare, they are of a serious or potentially life-threatening nature, which is the reason they are included in official warnings.

How to Store and Dispose of Analgin bufus (Metamizole Sodium Injection)

The storage and disposal of Analgin bufus must strictly adhere to the conditions mandated by official regulatory labeling to ensure product stability and safety.

Storage Requirements

Item	Mandatory Requirement Statement
Temperature Range	Store between 15°C and 30°C (Controlled Room Temperature).
Light/Container	Must be protected from light and kept in the original container.
Handling Constraints	Do not freeze the injectable solution.
Child Safety	Store out of the sight and reach of children.

Disposal Instructions

Following regulatory guidance, any unused solution remaining after opening the ampoule must be immediately discarded.

Unused or expired product must be disposed of via an approved waste disposal plant or returned to a drug take-back program. Disposal of the product or residues into wastewater or the environment is prohibited.